Skullcandy® Expands Sport Performance Line with Method® Wireless Earbuds
Sep 26, 2016 12:01 pm UTC| Business
PARK CITY, Utah, Sept. 26, 2016 -- Skullcandy, Inc. (NASDAQ:SKUL), the performance and lifestyle audio brand founded at the intersection of music, sports, technology, and creative culture, is expanding its sports...
Skullcandy® Expands Sport Performance Line with Method® Wireless Earbuds
Sep 26, 2016 12:01 pm UTC| Business
PARK CITY, Utah, Sept. 26, 2016 -- Skullcandy, Inc. (NASDAQ:SKUL), the performance and lifestyle audio brand founded at the intersection of music, sports, technology, and creative culture, is expanding its sports...
Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
Sep 26, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., Sept. 26, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo,...
Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
Sep 26, 2016 12:01 pm UTC| Business
CAMBRIDGE, Mass., Sept. 26, 2016 -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo,...
Sep 26, 2016 12:01 pm UTC| Business
TEL AVIV, Israel, Sept. 26, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced that Zohar Argov, MD, Special Medical Advisor to the Executive...
Sep 26, 2016 12:01 pm UTC| Business
TEL AVIV, Israel, Sept. 26, 2016 -- Bioblast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, today announced that Zohar Argov, MD, Special Medical Advisor to the Executive...
Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study
Sep 26, 2016 12:00 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2016 -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today...